Compare NXDT & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXDT | ADAG |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.1M | 260.3M |
| IPO Year | N/A | 2020 |
| Metric | NXDT | ADAG |
|---|---|---|
| Price | $5.36 | $4.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 137.6K | ★ 270.7K |
| Earning Date | 01-01-0001 | 04-01-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $1.44 |
| 52 Week High | $5.61 | $4.85 |
| Indicator | NXDT | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 63.49 | 62.38 |
| Support Level | $4.43 | $3.21 |
| Resistance Level | $5.55 | $4.66 |
| Average True Range (ATR) | 0.25 | 0.45 |
| MACD | 0.08 | 0.09 |
| Stochastic Oscillator | 93.95 | 75.46 |
NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.